Amgen, Inc. vs Omnicom Group Inc. — how do they compare? Amgen, Inc. trades at $412.77 (market cap $224.14B), while Omnicom Group Inc. trades at $85.74 (market cap $23.58B). The key difference: Amgen, Inc. is far larger — about 9.5× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals.
| AMGN | OMC | |
|---|---|---|
Market Cap | $224.14B | $23.58B |
Sector | Health | Media |
52-Week High | $417.20 | $86.22 |
52-Week Low | $271.18 | $67.27 |
Enterprise Value | $267.45B | $31.66B |
Dividend Yield | 2.43% | 3.72% |
Trailing returns across standard periods
Latest headlines on both assets
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →